Current Report Filing (8-k)
January 21 2022 - 7:16AM
Edgar (US Regulatory)
false
0001671584
0001671584
2022-01-21
2022-01-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2022
APTEVO THERAPEUTICS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
001-37746
|
81-1567056
|
|
|
(State or Other Juris-
diction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
2401 4th Avenue, Suite 1050
Seattle, Washington
|
98121
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (206) 838-0500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
APVO
|
|
The Nasdaq Stock Market LLC
|
|
|
|
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 21, 2022, Fuad El-Hibri, Chairman of the Board of Directors (“Board”) of Aptevo Therapeutics Inc. (“Company”), notified the Company of his retirement and resignation as a director of the Company, effective April 1, 2022. Mr. El-Hibri’s retirement is not the result of any dispute or disagreement with the Company, its management or the Board. It is expected that Mr. El-Hibri will be available following his retirement as needed on an advisory and consulting basis on terms to be agreed by the Company and Mr. El-Hibri.
On January 21, 2022, the Board appointed John Niederhuber, M.D. as Chairman of the Board effective April 1, 2022. Dr. Niederhuber has served on our Board and as our Vice Chairman (previously lead independent director) since August 2016. Also effective April 1, 2022, the size of the Company’s Board of Directors will be reduced from seven to six directors.
Item 7.01. Regulation FD Disclosure.
On January 21, 2022, the Company issued a press release regarding Mr. El-Hibri’s retirement and Dr. Niederhuber’s appointment as Chairman of the Board, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
APTEVO THERAPEUTICS INC.
|
|
|
|
Date: January 21, 2022
|
By:
|
/s/ Marvin L. White
|
|
|
|
Marvin L. White
|
|
|
President and Chief Executive Officer
|
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jul 2023 to Jul 2024